Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease

Abstract. Objective:. To validate and compare the performance of four risk stratification tools—the DEVI (Adverse Cardiac Events in Valvular Rheumatic Heart Disease in Pregnancy) score, Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) score, Cardiac Disease in Pregnancy II (CARPREG II), and modif...

Full description

Saved in:
Bibliographic Details
Main Authors: Malini Sukayogula, Tarakeswari Surapaneni, Anish Keepanasseril, Jue Li, Yang Pan
Format: Article
Language:English
Published: Wolters Kluwer Health 2025-07-01
Series:Maternal-Fetal Medicine
Online Access:http://journals.lww.com/10.1097/FM9.0000000000000291
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850067655989395456
author Malini Sukayogula
Tarakeswari Surapaneni
Anish Keepanasseril
Jue Li
Yang Pan
author_facet Malini Sukayogula
Tarakeswari Surapaneni
Anish Keepanasseril
Jue Li
Yang Pan
author_sort Malini Sukayogula
collection DOAJ
description Abstract. Objective:. To validate and compare the performance of four risk stratification tools—the DEVI (Adverse Cardiac Events in Valvular Rheumatic Heart Disease in Pregnancy) score, Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) score, Cardiac Disease in Pregnancy II (CARPREG II), and modified WHO (mWHO) classification—in predicting adverse cardiac events during pregnancy in women with valvular heart disease (VHD). Methods:. This retrospective cohort study was conducted at Fernandez Hospital, a tertiary care referral center in Hyderabad, India, utilizing clinical data from pregnancies managed between January 2011 and December 2023. The primary outcome was the development of composite adverse cardiac events. Discriminative ability was assessed using the area under the receiver operating characteristic curve (AUC), calibration was evaluated via calibration plots, and clinical utility was determined by decision curve analysis (DCA). Categorical variables were reported as frequencies and percentages and continuous variables were presented as means with standard deviations or medians with interquartile ranges. Individual risk assessment was conducted using both the CARPREG II and DEVI risk stratification models, while the ZAHARA score was calculated by aggregating weighted parameters according to established scoring criteria. Results:. The study enrolled 176 women and analyzed 205 pregnancies with adverse cardiac events in 19 pregnancies (9.3%). The DEVI score demonstrated superior discrimination (AUC = 0.846, 95% CI: 0.765-0.927, P < 0.001), followed by mWHO (AUC = 0.826, 95% CI: 0.736–0.917, P < 0.001), CARPREG II (AUC = 0.762, 95% CI: 0.652–0.872, P < 0.001), and ZAHARA (AUC = 0.716, 95% CI: 0.628–0.803, P < 0.001). Calibration plots revealed an overestimation of risk at higher probabilities for DEVI and CARPREG II. DCA indicated net clinical benefit for both tools at 10–30% threshold probabilities. Conclusion:. The DEVI score showed the highest discriminative performance, though its calibration and clinical utility were comparable to CARPREG II. These findings support its use for risk stratification in pregnant women with VHD, particularly in resource-limited settings where rheumatic VHD predominates.
format Article
id doaj-art-a44acac6fdc640328d93448d75ef22dc
institution DOAJ
issn 2096-6954
2641-5895
language English
publishDate 2025-07-01
publisher Wolters Kluwer Health
record_format Article
series Maternal-Fetal Medicine
spelling doaj-art-a44acac6fdc640328d93448d75ef22dc2025-08-20T02:48:15ZengWolters Kluwer HealthMaternal-Fetal Medicine2096-69542641-58952025-07-017314515010.1097/FM9.0000000000000291202507000-00003Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart DiseaseMalini Sukayogula0Tarakeswari Surapaneni1Anish Keepanasseril2Jue LiYang Pan1 Department of Obstetrics and Gynecology, and Obstetric Medicine, Fernandez Hospital, Hyderabad, Telangana 500029, India1 Department of Obstetrics and Gynecology, and Obstetric Medicine, Fernandez Hospital, Hyderabad, Telangana 500029, India2 Department of Obstetrics and Gynecology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry 605006, IndiaAbstract. Objective:. To validate and compare the performance of four risk stratification tools—the DEVI (Adverse Cardiac Events in Valvular Rheumatic Heart Disease in Pregnancy) score, Zwangerschap bij Aangeboren Hartafwijking (ZAHARA) score, Cardiac Disease in Pregnancy II (CARPREG II), and modified WHO (mWHO) classification—in predicting adverse cardiac events during pregnancy in women with valvular heart disease (VHD). Methods:. This retrospective cohort study was conducted at Fernandez Hospital, a tertiary care referral center in Hyderabad, India, utilizing clinical data from pregnancies managed between January 2011 and December 2023. The primary outcome was the development of composite adverse cardiac events. Discriminative ability was assessed using the area under the receiver operating characteristic curve (AUC), calibration was evaluated via calibration plots, and clinical utility was determined by decision curve analysis (DCA). Categorical variables were reported as frequencies and percentages and continuous variables were presented as means with standard deviations or medians with interquartile ranges. Individual risk assessment was conducted using both the CARPREG II and DEVI risk stratification models, while the ZAHARA score was calculated by aggregating weighted parameters according to established scoring criteria. Results:. The study enrolled 176 women and analyzed 205 pregnancies with adverse cardiac events in 19 pregnancies (9.3%). The DEVI score demonstrated superior discrimination (AUC = 0.846, 95% CI: 0.765-0.927, P < 0.001), followed by mWHO (AUC = 0.826, 95% CI: 0.736–0.917, P < 0.001), CARPREG II (AUC = 0.762, 95% CI: 0.652–0.872, P < 0.001), and ZAHARA (AUC = 0.716, 95% CI: 0.628–0.803, P < 0.001). Calibration plots revealed an overestimation of risk at higher probabilities for DEVI and CARPREG II. DCA indicated net clinical benefit for both tools at 10–30% threshold probabilities. Conclusion:. The DEVI score showed the highest discriminative performance, though its calibration and clinical utility were comparable to CARPREG II. These findings support its use for risk stratification in pregnant women with VHD, particularly in resource-limited settings where rheumatic VHD predominates.http://journals.lww.com/10.1097/FM9.0000000000000291
spellingShingle Malini Sukayogula
Tarakeswari Surapaneni
Anish Keepanasseril
Jue Li
Yang Pan
Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease
Maternal-Fetal Medicine
title Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease
title_full Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease
title_fullStr Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease
title_full_unstemmed Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease
title_short Validation of Risk Scoring Systems in Predicting Adverse Cardiac Outcomes in Pregnant Women With Valvular Heart Disease
title_sort validation of risk scoring systems in predicting adverse cardiac outcomes in pregnant women with valvular heart disease
url http://journals.lww.com/10.1097/FM9.0000000000000291
work_keys_str_mv AT malinisukayogula validationofriskscoringsystemsinpredictingadversecardiacoutcomesinpregnantwomenwithvalvularheartdisease
AT tarakeswarisurapaneni validationofriskscoringsystemsinpredictingadversecardiacoutcomesinpregnantwomenwithvalvularheartdisease
AT anishkeepanasseril validationofriskscoringsystemsinpredictingadversecardiacoutcomesinpregnantwomenwithvalvularheartdisease
AT jueli validationofriskscoringsystemsinpredictingadversecardiacoutcomesinpregnantwomenwithvalvularheartdisease
AT yangpan validationofriskscoringsystemsinpredictingadversecardiacoutcomesinpregnantwomenwithvalvularheartdisease